Big pharma, Insight journal - Dealtalk, M&A

Big pharma GSK addresses Human Genome poison pill

Posted on 23 May 2012

Tags: , ,

GSK, a big pharma company on Wednesday, May 23, tweaked the terms of its hostile $2.59  billion offer for Human Genome Sciences Inc. to address a poison pill mechanism  its target put in place last week.

Human Genome's plan, implemented as it  reiterated its rejection of the offer on May 17, dilutes holdings should a third  party attempt to buy up 15% or more of its stock without the board's  support.

The big pharma company, GlaxoSmithKline said it has added a condition to its offer  "requiring HGS to redeem the pill or, alternatively, GSK being satisfied in its  reasonable judgment that the pill has been invalidated or is otherwise  inapplicable to GSK's acquisition of HGS."

Human Genome, of Rockville,  Md., rejected the London company's initially friendly, $13 per-share offer in  April, instead hiring Credit Suisse Group and Goldman, Sachs & Co. to  conduct a formal sales process.

GlaxoSmithKline, which has been a partner  of Human Genome since 1993, declined to participate, and on May 9 took its offer  directly to shareholders.

Read the full article at The Deal (link no longer available)



Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies

Report: Merger and Acquisition Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply